\BOOKMARK [0][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.2}{Preface}{}% 2
\BOOKMARK [0][-]{chapter*.3}{Table of Contents}{}% 3
\BOOKMARK [0][-]{chapter*.4}{List of Tables}{}% 4
\BOOKMARK [0][-]{chapter*.5}{List of Figures}{}% 5
\BOOKMARK [0][-]{chapter*.6}{List of Abbreviations}{}% 6
\BOOKMARK [0][-]{chapter*.7}{Acknowledgments}{}% 7
\BOOKMARK [0][-]{chapter.1}{1 Introduction}{}% 8
\BOOKMARK [1][-]{section.1.1}{1.1 Overcoming The Clinical Reality}{chapter.1}% 9
\BOOKMARK [1][-]{section.1.2}{1.2 Genomics-Driven Oncology}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.2.1}{1.2.1 Definitions}{section.1.2}% 11
\BOOKMARK [2][-]{subsection.1.2.2}{1.2.2 Genomic Alterations in Cancer Pathogenesis}{section.1.2}% 12
\BOOKMARK [2][-]{subsection.1.2.3}{1.2.3 Clinical Deployment of Targeted Cancer Therapies}{section.1.2}% 13
\BOOKMARK [2][-]{subsection.1.2.4}{1.2.4 Advances in DNA Sequencing Technologies}{section.1.2}% 14
\BOOKMARK [1][-]{section.1.3}{1.3 Next-Generation Sequencing Technologies}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.3.1}{1.3.1 Sequencing by Ligation}{section.1.3}% 16
\BOOKMARK [2][-]{subsection.1.3.2}{1.3.2 Sequencing by Synthesis}{section.1.3}% 17
\BOOKMARK [1][-]{section.1.4}{1.4 Objectives}{chapter.1}% 18
\BOOKMARK [1][-]{section.1.5}{1.5 Genomics-Driven Oncology}{chapter.1}% 19
\BOOKMARK [2][-]{subsection.1.5.1}{1.5.1 Definitions}{section.1.5}% 20
\BOOKMARK [2][-]{subsection.1.5.2}{1.5.2 Genomic Alterations in Cancer Pathogenesis}{section.1.5}% 21
\BOOKMARK [2][-]{subsection.1.5.3}{1.5.3 Clinical Deployment of Targeted Cancer Therapies}{section.1.5}% 22
\BOOKMARK [2][-]{subsection.1.5.4}{1.5.4 Advances in DNA Sequencing Technologies}{section.1.5}% 23
\BOOKMARK [1][-]{section.1.6}{1.6 Applications of Massively Parallel Sequencing}{chapter.1}% 24
\BOOKMARK [2][-]{subsection.1.6.1}{1.6.1 Targeted Resequencing}{section.1.6}% 25
\BOOKMARK [2][-]{subsection.1.6.2}{1.6.2 Whole Exome Sequencing}{section.1.6}% 26
\BOOKMARK [2][-]{subsection.1.6.3}{1.6.3 Whole Genome Sequencing}{section.1.6}% 27
\BOOKMARK [1][-]{section.1.7}{1.7 Bioinformatics Tools for Variant Calling}{chapter.1}% 28
\BOOKMARK [2][-]{subsection.1.7.1}{1.7.1 Types of Genomic Alterations}{section.1.7}% 29
\BOOKMARK [2][-]{subsection.1.7.2}{1.7.2 Variant Calling Pipeline}{section.1.7}% 30
\BOOKMARK [2][-]{subsection.1.7.3}{1.7.3 Variant Calling Algorithms}{section.1.7}% 31
\BOOKMARK [2][-]{subsection.1.7.4}{1.7.4 Variant Curation and Interpretation}{section.1.7}% 32
\BOOKMARK [1][-]{section.1.8}{1.8 Challenges in Clinical Genomics}{chapter.1}% 33
\BOOKMARK [2][-]{subsection.1.8.1}{1.8.1 DNA Damage by Formalin Fixation}{section.1.8}% 34
\BOOKMARK [2][-]{subsection.1.8.2}{1.8.2 Lack of Matched Normal DNA}{section.1.8}% 35
\BOOKMARK [2][-]{subsection.1.8.3}{1.8.3 Variant of Unknown Significance}{section.1.8}% 36
\BOOKMARK [2][-]{subsection.1.8.4}{1.8.4 Incidental Findings}{section.1.8}% 37
\BOOKMARK [1][-]{section.1.9}{1.9 Pharmacogenomics in Clinical Oncology}{chapter.1}% 38
\BOOKMARK [2][-]{subsection.1.9.1}{1.9.1 Targeted Therapies}{section.1.9}% 39
\BOOKMARK [2][-]{subsection.1.9.2}{1.9.2 Chemotherapy-Associated Morbidities}{section.1.9}% 40
\BOOKMARK [1][-]{section.1.10}{1.10 Summary}{chapter.1}% 41
\BOOKMARK [0][-]{chapter.2}{2 Materials and Methods}{}% 42
\BOOKMARK [1][-]{section.2.1}{2.1 Patient Samples}{chapter.2}% 43
\BOOKMARK [1][-]{section.2.2}{2.2 DNA Extraction, Library Preparation, and Illumina Sequencing}{chapter.2}% 44
\BOOKMARK [1][-]{section.2.3}{2.3 Variant Calling Pipeline}{chapter.2}% 45
\BOOKMARK [1][-]{section.2.4}{2.4 Data Analysis and Visualization}{chapter.2}% 46
\BOOKMARK [0][-]{chapter.3}{3 Results}{}% 47
\BOOKMARK [1][-]{section.3.1}{3.1 }{chapter.3}% 48
\BOOKMARK [1][-]{section.3.2}{3.2 Sequencing Depth is Comparable between FFPE and FF-PB Samples}{chapter.3}% 49
\BOOKMARK [1][-]{section.3.3}{3.3 Sequencing Depth is Comparable between FFPE and FF-PB Samples}{chapter.3}% 50
\BOOKMARK [0][-]{chapter.4}{4 Discussion and Conclusion}{}% 51
\BOOKMARK [1][-]{section.4.1}{4.1 Conclusion}{chapter.4}% 52
\BOOKMARK [0][-]{chapter*.12}{Bibliography}{}% 53
\BOOKMARK [0][-]{appendix.A}{A Supporting Materials}{}% 54
